A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer

Mayo Clinic Proceedings

Volumn 77, Issue 3, 2002, Pages 219-225

  Roberts, Rosebud O ^a   Jacobson, Debra J ^a   Girman, Cynthia J ^a,b   Rhodes, Thomas ^b   Lieber, Michael M ^a   Jacobsen, Steven J ^a  

^a MAYO CLINIC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

BPH = benign prostatic hyperplasia; CI = confidence interval; COX 2 = cyclooxygenase 2; DRE = digital rectal examination; NSAID = nonsteroidal anti inflammatory drug; OR = odds ratio; PSA = prostate specific antigen

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CORRELATION ANALYSIS; DISEASE COURSE; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; UNITED STATES;

EID: 0036183346     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.3.219     Document Type: Article

References (48)

1. Cancer statistics, 2002
2. Descriptive epidemiology of testicular and prostatic cancer in Los Angeles
3. Geographic pathology of latent prostatic carcinoma
4. Diet and prostatic cancer: A case-control study in Hawaii
5. Familial patterns of prostate cancer: A case-control analysis
6. Selenium and prostate cancer prevention
7. Vitamin E, alpha- and gamma-tocopherol, and prostate cancer
8. Vitamin D analogue EB 1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
9. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells
10. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate
11. Evaluation of biomarker modulation by fenretinide in prostate cancer patients
12. Prostate cancer chemoprevention by green tea
13. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial
14. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
15. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing
16. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study
17. Low incidence of colorectal cancer in patients with rheumatoid arthritis
18. Nonsteroidal antiinflammatory drugs and colorectal cancer
19. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
20. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
21. Aspirin and the risk of colorectal cancer in women
22. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
23. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer
24. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage
25. Over-the-counter analgesics and risk of ovarian cancer
26. Inhibition of cyclooxygenase: A novel approach to cancer prevention
27. The "aspirin" of the new millennium: Cyclooxygenase-2 inhibitors
28. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
29. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
30. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma
31. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells
32. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
33. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines
34. Up-regulation of cyclooxygenase-2 by product-prostaglandin E2
35. Aspirin use and chronic diseases: A cohort study of the elderly
36. Non-steroidal anti-inflammatory drugs and prostate cancer progression
37. Relative risk of malignant tumors in analgesic abusers: Effects of long-term intake of aspirin
38. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study
39. History of the Rochester Epidemiology Project
40. The prevalence of prostatism: A population-based survey of urinary symptoms
41. A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County Study of urinary symptoms and health status among men
42. The patient record in epidemiology
43. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old
44. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men
45. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
46. Pathology of premalignant lesions and carcinoma of the prostate in African-American men
47. The natural history of prostatism: The effects of non-response bias